Kotak Upgrades Mankind Pharma as Domestic Business Recovery Emerges

Kotak Institutional Equities changed its view of Mankind Pharma’s shares to a more positive one.

This is called an upgrade.

The research firm believes the company’s main domestic business is beginning to recover.

It said this recovery is now clearly visible.

The business had previously been affected by a long restructuring period.

Kotak’s view helped support the upgrade.

The article also says Mankind Pharma’s price target is among the top five on the street.

The exact price target was not provided.